To search for more efficient anti-Alzheimer agents, a series of novel sarsasapogenin-triazolyl hybrids were designed, synthesized, and evaluated for their Aβ1−42 aggregationinhibitoryactivities. Most of these new hybrids displayed potent Aβ1−42 aggregation inhibition. In particular, the promising compounds 6j and 6o displayed a better ability to interrupt the formation of Aβ1−42 fibrils than curcumin